GoodRx Holdings Inc

GoodRx Holdings Inc(GDRX)股票分析

$3.540

-0.078 (-2.21%)收盤時

Loading chart…
最高
3.600
開盤
3.570
成交量加權均價
3.55
成交量
1.14M
市值
2.89B
最低
3.500
成交金額
4.04M
企業價值/稅息折舊攤銷前利潤(TTM)
7.89

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

AI 分析 of GoodRx Holdings Inc (GDRX)

買進

GoodRx Holdings Inc (GDRX) is a good buy right now at the current price of $3.54, especially considering its forward P/E ratio of 10.29, which suggests it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong year-to-date change of +28.73% and a recent 5-day change of +5.36%, indicating positive momentum. However, the main risk is the decline in net income reported for Q2 2026, which was $8.54 million, down from $12.84 million last year, reflecting potential profitability concerns.

估值指標

GoodRx Holdings Inc(GDRX)目前預期本益比為 10.29,5 年平均預期本益比為 35.23。

預期本益比

合理
5 年均值 P/E
35.23
目前P/E
10.29
高估
643.09
低估
-572.63

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
12.80
目前EV/EBITDA
7.89
高估
24.70
低估
0.89

預期股價營收比

合理
5 年均值 P/S
3.58
目前P/S
1.48
高估
7.13
低估
0.02

Alphio AI 對 GDRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%GDRX

$4.23

情境價格

基

基準

基準 · 50%GDRX

$3.42

情境價格

悲

悲觀

悲觀 · 25%GDRX

$3.21

情境價格

持有 GDRX 的大戶

S

Silver Lake Technology Management, L.L.C.

+ 持有GDRX

+8.71%

3個月報酬率

T

TCMI Inc.

+ 持有GDRX

+8.15%

3個月報酬率

事件時間軸

2026-09-03 (ET)

09:30:00

GoodRx Launches Family Plan for $24.99 Monthly

2026-08-05 (ET)

17:31:00

GoodRx Q2 Revenue $200.4M, Exceeds Consensus

17:30:00

Raises FY26 Adjusted EBITDA Outlook to $240M-$250M

2026-05-27 (ET)

09:10:00

GoodRx Launches GoodRx Companion Subscription at $14.99 per Month

2026-05-06 (ET)

17:10:00

Raises FY26 Adjusted EBITDA Outlook to Over $235M

資訊

GDRX 常見問題 —— 由 Alphio AI 解答

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications. It operates in the Technology sector (SERVICES-COMPUTER PROCESSING & DATA PREPARATION industry).

GoodRx Holdings Inc (GDRX) is a good buy right now at the current price of $3.54, especially considering its forward P/E ratio of 10.29, which suggests it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong year-to-date change of +28.73% and a recent 5-day change of +5.36%, indicating positive momentum. However, the main risk is the decline in net income reported for Q2 2026, which was $8.54 million, down from $12.84 million last year, reflecting potential profitability concerns.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易